No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
300 |
4. Check minimum number of eventsNone |
300 |
5. Include endpointsNone |
300 |
6. Filter based on genotype QC (FinnGen only) |
264 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of adrenal gland, including Hilmo
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of endocrine gland, including Hilmo
- Solid cancers, including Hilmo
- Malignant neoplasm, wide definition
- Malignant neoplasm, including Hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 264 | 137 | 127 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.06 |
| Median age at first event (years) | 58.06 | 54.74 | 61.64 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 280
- Matched controls
- 2800
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
268.5
300.6
144
11
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
69.2
136.0
76
15
C74.9
ICD-10 Finland
Malignant neoplasm: Adrenal gland, unspecified
+∞
111.0
99
*
130
Kela drug reimbursment
Malignant tumour
+∞
111.0
99
*
BCA31
NOMESCO Finland
Endoscopic unilateral adrenalectomy
392.4
106.9
101
*
C74.0
ICD-10 Finland
Malignant neoplasm: Cortex of adrenal gland
+∞
105.0
94
*
C74.1
ICD-10 Finland
Malignant neoplasm: Medulla of adrenal gland
+∞
94.2
85
*
H02AB09
ATC
hydrocortisone; systemic
26.9
92.9
68
33
H02AB02
ATC
dexamethasone; systemic
49.3
82.5
49
12
E27.5
ICD-10 Finland
Adrenomedullary hyperfunction
+∞
77.8
71
*
BCA30
NOMESCO Finland
Unilateral adrenalectomy
+∞
66.3
61
*
TPH07
NOMESCO Finland
Cathetrisation of artery
8.6
57.7
91
148
JN4BD
NOMESCO Finland
Extensive body CT
15.3
55.3
52
41
JN4AD
NOMESCO Finland
Body CT examination
12.7
51.6
55
53
A04AA01
ATC
ondansetron; systemic, rectal
15.1
49.8
47
37
8700/3-C74.1
ICD-O-3
Pheochromocytoma, NOS, of medulla of adrenal gland
+∞
46.1
43
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
17.1
46.0
40
27
8700/3-C74.9
ICD-O-3
Pheochromocytoma, NOS, of adrenal gland, NOS
+∞
43.9
41
*
8370/3-C74.0
ICD-O-3
Adrenal cortical carcinoma of cortex of adrenal gland
+∞
37.3
35
*
L01XX23
ATC
mitotane; oral
+∞
35.1
33
*
A03FA01
ATC
metoclopramide; systemic, rectal
5.5
34.7
84
202
A04AA02
ATC
granisetron; systemic, transdermal
376.6
33.6
33
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
13.3
32.2
32
27
Z51.5
ICD-10 Finland
Palliative care
8.9
26.6
35
44
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
25.4
24
*
WW500
NOMESCO Finland
Blood transfusion
10.6
23.6
27
28
H02AA02
ATC
fludrocortisone; oral
38.7
22.5
28
8
JN3AD
NOMESCO Finland
Abdominal CT examination
4.7
22.3
60
154
XW000
NOMESCO Finland
Bone marrow biopsy
21.1
21.8
32
17
N02AA05
ATC
oxycodone; systemic
4.2
21.7
69
201
WX402
NOMESCO Finland
General anaesthesia
3.7
21.3
92
331
ZXE20
NOMESCO Finland
More than three and less than five hours
4.4
21.3
62
169
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
21.1
20
*
ZXE10
NOMESCO Finland
More than one and less than three hours
3.3
21.1
131
591
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.3
20.5
37
66
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
20.0
19
*
XX3DW
NOMESCO Finland
Time consuming IT work
7.3
20.0
31
47
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
113.1
19.8
21
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.0
17.9
159
857
WX408
NOMESCO Finland
General anesthesy, balanced
3.2
17.8
95
385
L03AA02
ATC
filgrastim; parenteral
191.6
17.7
18
*
WZC00
NOMESCO Finland
Treatment plan or consultation
3.0
17.4
119
555
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.5
17.1
73
257
9500/3-C74.1
ICD-O-3
Neuroblastoma, NOS, of medulla of adrenal gland
+∞
16.8
16
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
16.8
16
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
180.3
16.7
17
*
BC1AD
NOMESCO Finland
CT of adrenal glands
25.1
15.3
21
9
B01AB05
ATC
enoxaparin; parenteral
2.9
15.3
100
449
WZC30
NOMESCO Finland
Teaching
3.5
15.0
59
196
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.0
14.9
48
139
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
84.7
14.7
16
*
BC5AQ
NOMESCO Finland
Chromaffine tissue SPECT with low dose CT
+∞
14.7
14
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
14.7
14
*
L01BC06
ATC
capecitabine; oral
+∞
14.7
14
*
Z31.5
ICD-10 Finland
Genetic counselling
5.1
14.4
32
69
ZX120
NOMESCO Finland
Intravenous
4.7
14.3
35
82
BC1CD
NOMESCO Finland
Very extensive CT of adrenal glands
45.0
14.3
17
*
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
15.8
13.8
22
15
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
13.6
13
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.0
13.6
74
298
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
22.5
13.5
19
9
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
12.7
55
193
EP1AE
NOMESCO Finland
Neck ultrasound examination
5.2
12.2
26
54
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
5.9
11.8
22
40
L03AA13
ATC
pegfilgrastim; parenteral
67.9
11.7
13
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
11.5
11
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
11.5
11
*
D35.59
ICD-10 Finland
Other paragangliom
+∞
11.5
11
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
11.5
11
*
BC5AN
NOMESCO Finland
Chromaffine and adrenergic tissue isotope imaging (MIBG)
+∞
11.5
11
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
12.6
11.5
20
17
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
11.3
11.5
21
20
JN3DG
NOMESCO Finland
Very extensive MRI examination with high intensity magnet
36.7
11.4
14
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
4.0
11.2
34
94
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
14.7
11.1
18
13
JN4CD
NOMESCO Finland
Very extensive body CT
16.4
11.0
17
11
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
62.4
10.7
12
*
E24.9
ICD-10 Finland
Cushing syndrome, unspecified
114.1
10.5
11
*
E24.8
ICD-10 Finland
Other Cushing syndrome
114.1
10.5
11
*
105
Kela drug reimbursment
Adrenal cortical hypofunction
114.1
10.5
11
*
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
+∞
10.5
10
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
10.5
10
*
Z85.8
ICD-10 Finland
Personal history of malignant neoplasms of other organs and systems
+∞
10.5
10
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
10.5
10
*
H03AA01
ATC
levothyroxine sodium; systemic
2.5
10.1
79
378
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
41.7
10.0
12
*
J01MA12
ATC
levofloxacin; systemic
2.8
10.0
60
252
ZXD10
NOMESCO Finland
Scheduled procedure
2.3
9.7
114
651
XX9AN
NOMESCO Finland
Complementary isotope examination or additional picture
57.0
9.7
11
*
WF002
NOMESCO Finland
Radical radiotherapy
57.0
9.7
11
*
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
57.0
9.7
11
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
10.6
9.7
18
18
I15.2
ICD-10 Finland
Hypertension secondary to endocrine disorders
103.4
9.5
10
*
2533
FHL
Unilateral removal of additional egg
103.4
9.5
10
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
9.4
9
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
9.4
9
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
+∞
9.4
9
*
115
Kela drug reimbursment
Breast cancer
+∞
9.4
9
*
A04AD12
ATC
aprepitant; systemic
+∞
9.4
9
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
9.4
9
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
9.4
9
*
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
9.4
9
*
GD1AD
NOMESCO Finland
Thorax CT examination
4.4
9.4
24
58
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
4.3
9.3
25
63
ZXE00
NOMESCO Finland
One hour or less
2.2
9.2
118
695
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
4.5
8.8
22
52
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.3
8.7
34
111
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.3
8.7
34
111
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
4.8
8.7
20
44
B01AB10
ATC
tinzaparin; parenteral
3.3
8.6
34
112
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
9.9
8.4
16
17
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
8.4
8
*
9101
FHL
Bone biopsy
+∞
8.4
8
*
KKB10
NOMESCO Finland
Excision of retroperitoneal tumour
+∞
8.4
8
*
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
+∞
8.4
8
*
1940B
ICD-9 Finland
Malignant neoplasm of other endocrine glands and related structures, Adrenal gland[NEUROBLASTOMA SUPRARENALIS]
+∞
8.4
8
*
BC1BD
NOMESCO Finland
Extensive CT of adrenal glands
+∞
8.4
8
*
N02AA01
ATC
morphine; systemic, rectal
17.8
8.1
12
7
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
7.3
7.9
18
26
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.2
7.8
33
113
ZX121
NOMESCO Finland
Central venous catheter
46.3
7.8
9
*
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
19.0
7.7
11
6
V04CD01
ATC
metyrapone; oral
+∞
7.3
7
*
JN7AQ
NOMESCO Finland
Somatostatin receptor SPET med low dose CT
+∞
7.3
7
*
L01AX03
ATC
temozolomide; systemic
+∞
7.3
7
*
9109
FHL
Other measure in this category
+∞
7.3
7
*
C74
ICD-10 Finland
Malignant neoplasm of adrenal gland
+∞
7.3
7
*
8370/3-C74.9
ICD-O-3
Adrenal cortical carcinoma of adrenal gland, NOS
+∞
7.3
7
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
7.3
7
*
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
7.3
7
*
Y77
ICPC
Malignant neoplasm prostate
+∞
7.3
7
*
116
Kela drug reimbursment
Prostate cancer
+∞
7.3
7
*
8010/3-C74.9
ICD-O-3
Carcinoma, NOS, of adrenal gland, NOS
+∞
7.3
7
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
+∞
7.3
7
*
YNB10
NOMESCO Finland
Collection of stem cells for transplant
+∞
7.3
7
*
8260/3-C73.9
ICD-O-3
Papillary adenocarcinoma, NOS, of thyroid gland
+∞
7.3
7
*
N05BA06
ATC
lorazepam; systemic, sublingual
3.8
7.3
23
65
N02AX02
ATC
tramadol; systemic, rectal
2.0
7.2
124
800
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.3
7.1
27
87
JAH00
NOMESCO Finland
Laparotomy
6.6
7.1
17
27
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.1
7.0
30
104
TPH04
NOMESCO Finland
Cathetrisation of vein
2.2
6.9
66
340
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
8.6
6.9
14
17
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.1
6.9
88
508
E04.9
ICD-10 Finland
Nontoxic goitre, unspecified
9.7
6.9
13
14
ZX090
NOMESCO Finland
Other technic of radiotherapy
41.1
6.8
8
*
KAC10
NOMESCO Finland
Total nephrectomy with capsule
71.4
6.5
7
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
71.4
6.5
7
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.3
6.4
51
243
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
3.5
6.3
22
67
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
6.3
6
*
Q85.82
ICD-10 Finland
of Hipple-Lindau syndrome
+∞
6.3
6
*
D48.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other specified sites
+∞
6.3
6
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
6.3
6
*
WW300
NOMESCO Finland
Transfer of autologic stem cells
+∞
6.3
6
*
A79
ICPC
Malignancy NOS
+∞
6.3
6
*
HAC20
NOMESCO Finland
Total mastectomy
+∞
6.3
6
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
6.3
6
*
WB203
NOMESCO Finland
Simple adjuvant hormone therapy of malignancy
+∞
6.3
6
*
WX1CG
NOMESCO Finland
Extensive total body MRI with high intensity magnet
+∞
6.3
6
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
6.3
6
*
C73.91
ICD-10 Finland
Papillary carcinoma of the thyroid gland (thyroid gland)
+∞
6.3
6
*
ZXE30
NOMESCO Finland
More than five and less than seven hours
4.1
6.3
17
43
A41.9
ICD-10 Finland
Sepsis, unspecified
4.1
6.3
17
43
JN1CD
NOMESCO Finland
Very extensive CT examination of upper part of abdomen
27.3
6.3
8
*
Z2446
NOMESCO Finland
Social worker
2.9
6.2
31
117
R11
ICD-10 Finland
Nausea and vomiting
2.6
6.2
38
160
KA1MN
NOMESCO Finland
Glomerular filtration rate (GFR) Isotope mesurement
12.9
6.1
10
8
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
8.9
6.1
12
14
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
123
38
56.94
201.93
4.7
1.4
2.83
0.20
nmol/l
0.73
96
29
113
40
46.69
177.20
4.7
1.4
—
—
nmol/l
—
0
0
76
37
27.82
104.13
1.4
1.3
231.45
403.78
pmol/l
1.39
65
32
70
42
21.89
87.06
4.3
1.6
75.61
22.51
ng/l
3.01
70
42
31
8
43.28
25.46
1.5
1.5
415.37
58.00
nmol/24h
—
31
8
49
104
5.50
22.72
3.6
1.5
4.44
2.30
ug/l
0.90
40
80
169
910
3.16
19.65
9.8
4.7
33.99
36.06
g/l
3.77
164
856
168
966
2.85
16.24
4.2
2.5
—
—
estimate
—
0
0
186
1132
2.92
16.06
15.6
7.8
1.21
1.21
mmol/l
0.34
157
989
60
194
3.66
15.97
2.3
2.6
0.21
0.21
g/l
0.04
54
177
50
143
4.04
15.85
6.7
3.5
1.22
1.23
mmol/l
0.17
50
119
206
1351
2.99
14.97
10.7
5.4
6.49
6.69
mmol/l
0.70
200
1273
65
235
3.30
14.45
7.1
9.3
0.42
1.12
mmol/l
0.63
58
202
101
487
2.68
13.20
3.4
2.7
4.50
5.02
e6/l
0.24
93
437
101
505
2.56
12.09
3.7
2.1
—
—
—
0
0
188
1273
2.45
11.17
23.0
7.1
4.12
4.14
e9/l
0.04
171
1095
117
649
2.38
10.97
5.0
3.4
0.33
0.33
e6/l
0.03
96
455
124
706
2.36
10.94
3.1
2.3
51.10
65.69
u/l
1.35
118
652
128
743
2.33
10.75
5.0
3.5
55.11
153.94
e6/l
0.53
103
549
120
688
2.30
10.27
7.3
2.0
2.35
2.36
mmol/l
0.38
114
603
64
276
2.71
10.15
1.9
1.7
—
—
—
0
0
21
26
8.64
10.03
2.9
3.9
13.26
33.62
mu/l
0.65
21
26
40
134
3.32
9.89
1.6
1.4
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
22
50
4.69
9.26
2.3
4.6
0.34
0.40
iu/ml
0.30
16
31
60
264
2.62
9.08
2.1
1.8
—
—
—
0
0
75
367
2.43
9.07
2.3
1.8
—
—
—
0
0
50
201
2.81
9.01
5.0
2.9
—
—
—
0
0
50
202
2.80
8.92
18.2
15.1
24.99
24.64
mmol/l
0.21
50
202
22
52
4.51
8.83
3.0
2.0
26.82
16.35
u/ml
0.38
17
43
220
1679
2.45
8.82
15.5
5.7
95.40
81.33
u/l
2.02
214
1559
19
25
8.07
8.80
1.8
1.4
—
—
—
0
0
23
57
4.31
8.71
1.8
1.4
—
—
—
0
0
22
53
4.42
8.63
1.9
1.5
—
—
—
0
0
18
23
8.28
8.51
1.3
1.3
—
—
—
0
0
76
388
2.32
8.28
2.6
2.6
11.42
13.34
umol/l
1.48
76
361
104
612
2.11
7.92
2.4
2.3
2.84
2.78
mg/l
0.10
89
529
27
81
3.58
7.88
3.8
2.0
13.44
8.35
u/l
0.69
18
59
21
55
4.05
7.40
1.4
1.5
—
—
—
0
0
7
0
+∞
7.32
3.1
0.0
20.49
—
u/ml
—
7
0
55
256
2.43
7.31
7.4
3.2
11.54
6.99
umol/l
0.28
49
218
17
26
6.89
7.23
1.8
1.2
—
—
—
0
0
10
5
20.66
7.18
2.0
1.0
40.18
1.95
umol/24h
—
10
5
12
10
12.47
7.15
5.3
4.6
—
—
—
0
0
23
69
3.54
6.71
3.8
3.7
102.78
90.35
%
1.49
23
69
18
46
4.11
6.54
2.8
1.5
—
—
—
0
0
18
36
5.27
6.30
1.8
1.3
—
—
—
0
0
20
58
3.64
6.13
1.6
3.4
—
—
—
0
0
20
60
3.51
5.84
1.1
1.3
—
—
—
0
0
11
13
8.75
5.61
1.1
1.2
177.17
320.50
pmol/l
—
6
8
17
37
4.82
5.59
1.5
1.3
—
—
—
0
0
117
789
1.83
5.58
4.8
3.0
29.99
33.81
u/l
0.66
109
743
41
191
2.34
5.39
6.1
8.7
2.35
1.47
mmol/l
0.72
35
139
10
11
9.38
5.33
1.8
1.1
—
—
—
0
0
27
103
2.79
5.33
3.3
2.0
20.20
18.88
iu/l
0.07
20
78
19
59
3.38
5.27
4.9
2.8
2.36
1.42
index
0.51
14
33
186
1471
1.79
4.93
5.7
4.5
10.00
789.72
e6/l
—
6
18
193
1548
1.79
4.82
4.5
3.4
70.27
43.86
u/l
1.95
184
1455
8
7
11.71
4.81
1.9
1.0
—
—
—
0
0
15
35
4.47
4.70
3.4
3.9
4.94
4.80
kpa
0.24
15
35
10
14
7.36
4.69
5.4
1.8
0.60
0.86
index
—
10
14
218
1823
1.88
4.64
6.6
4.2
14.72
14.82
pmol/l
0.22
204
1668
8
8
10.25
4.55
2.0
1.0
—
—
—
0
0
40
200
2.17
4.45
2.9
2.1
25.72
36.18
u/l
1.23
32
164
30
133
2.41
4.40
1.9
1.5
—
—
—
0
0
11
20
5.68
4.33
1.5
1.2
—
—
—
0
0
8
9
9.11
4.30
1.9
1.0
—
—
—
0
0
66
403
1.83
4.18
6.4
2.0
2.48
2.44
mmol/l
1.68
61
349
63
387
1.81
3.89
5.0
3.4
2.69
2.20
e6/l
0.18
33
188
8
11
7.45
3.88
2.9
1.3
4.90
4.13
nmol/l
—
8
11
13
33
4.08
3.85
2.1
8.9
—
267.40
—
0
5
135
1022
1.62
3.83
3.6
2.8
74.67
75.50
nmol/l
0.13
128
911
100
710
1.64
3.64
3.2
3.5
2785.91
1303.98
ng/l
0.95
82
598
206
1743
1.69
3.64
5.0
4.4
15.49
11.28
mm/h
2.65
195
1617
10
22
4.67
3.46
5.4
2.0
13.10
15.00
index
—
10
14
11
27
4.20
3.43
1.1
1.1
—
—
—
0
0
7
10
7.15
3.38
2.1
5.5
1.88
1.82
ug/l
—
7
10
65
422
1.70
3.29
4.7
3.1
0.32
0.92
e6/l
3.75
35
221
143
1125
1.55
3.28
3.8
3.1
184.91
99.98
ug/l
2.38
137
1059
6
7
8.72
3.28
2.3
2.1
—
—
—
0
0
12
37
3.34
2.97
2.0
1.2
—
—
—
0
0
9
22
4.19
2.90
2.0
1.1
—
—
—
0
0
89
650
1.54
2.76
3.9
3.2
0.00
0.00
estimate
-0.00
38
191
13
48
2.79
2.76
1.9
1.3
—
—
—
0
0
66
451
1.61
2.72
5.2
4.0
571.79
301.16
ng/l
0.26
52
340
13
50
2.68
2.57
2.1
1.7
—
—
—
0
0
89
666
1.49
2.42
1.9
1.7
18.91
20.33
nmol/l
0.38
84
561
45
288
1.67
2.39
18.7
6.0
2.13
1.69
mmol/l
0.37
40
241
10
33
3.10
2.38
1.9
1.2
—
—
—
0
0
6
13
4.69
2.28
2.0
1.5
—
—
—
0
0
10
35
2.92
2.23
1.2
1.5
—
—
—
0
0
10
35
2.92
2.23
1.2
1.5
—
—
—
0
0
7
19
3.75
2.16
1.6
1.0
—
—
—
0
0
6
15
4.06
2.05
1.5
1.3
—
—
—
0
0
64
462
1.50
2.05
1.9
1.8
454.42
30789907.41
pmol/l
0.50
50
380
10
38
2.69
2.02
1.9
1.2
—
—
—
0
0
10
38
2.69
2.02
3.8
6.2
8.16
9.69
pmol/l
—
10
38
12
52
2.37
1.90
2.5
1.2
1.51
1.39
ratio
—
6
30
8
28
2.91
1.87
1.1
1.4
—
—
—
0
0
13
59
2.26
1.87
1.7
1.9
—
—
—
0
0
13
59
2.26
1.87
1.7
1.9
176.25
277.18
u/ml
—
8
22
84
653
1.41
1.81
3.7
3.7
0.00
0.00
estimate
-0.00
39
218
8
29
2.81
1.80
6.0
5.9
11.70
10.40
mg/l
—
8
29
91
723
1.38
1.72
2.4
2.1
172.55
284.27
u/l
0.61
86
685
5
14
3.62
1.62
1.4
1.8
—
—
—
0
0
7
158
0.43
1.60
1.0
1.1
—
—
—
0
0
13
65
2.05
1.51
1.5
1.6
0.92
0.72
nmol/l
0.57
13
55
142
1228
1.32
1.49
4.3
3.8
0.00
0.00
estimate
-0.00
44
228
106
880
1.33
1.48
5.3
3.6
33.67
40.52
ng/l
0.44
77
614
26
165
1.63
1.46
3.3
2.4
58.18
68.97
ml/min/173m2
0.54
11
63
7
28
2.54
1.46
1.1
1.5
—
—
—
0
0
8
165
0.47
1.40
1.6
1.9
3.20
3.53
mmol/l
—
8
131
144
1256
1.30
1.39
4.3
3.9
0.00
0.02
estimate
0.68
40
219
66
516
1.37
1.36
2.5
1.8
1.19
0.99
mg/l
0.42
49
397
12
61
2.01
1.35
1.3
1.3
238.83
315.26
ug/g
—
6
36
234
2191
1.41
1.34
5.1
5.0
5.90
5.95
mmol/l
0.18
224
2008
142
1245
1.29
1.28
4.3
3.8
0.00
0.00
estimate
-0.00
45
233
233
2186
1.39
1.26
7.2
5.2
1.79
1.94
mu/l
1.00
219
2007
121
1042
1.28
1.25
1.9
2.0
83.77
96.89
pmol/l
2.10
58
515
5
19
2.66
1.22
1.0
1.0
—
—
—
0
0
8
38
2.14
1.19
1.1
1.3
—
—
—
0
0
6
26
2.34
1.19
1.2
1.6
—
—
—
0
0
17
268
0.61
1.16
9.2
6.9
—
—
—
0
0
5
21
2.41
1.09
1.0
1.2
158.80
95.00
pmol/l
—
5
21
116
1008
1.26
1.08
2.5
1.9
1.85
1.34
mmol/l
1.62
106
870
24
163
1.52
1.06
1.3
1.3
62.90
99.84
u/ml
—
10
65
105
906
1.25
1.03
3.9
3.6
0.00
0.03
estimate
1.02
37
192
10
53
1.92
1.02
1.4
1.7
—
—
—
0
0
72
600
1.27
0.94
3.3
2.5
333.84
350.70
umol/l
0.58
63
524
17
110
1.58
0.93
1.5
1.6
—
—
—
0
0
222
2101
1.27
0.88
32.7
12.1
80.82
81.76
ml/min/173m2
0.24
207
1918
41
512
0.77
0.82
1.5
1.8
—
—
—
0
0
8
48
1.69
0.79
2.3
2.8
9.45
6.41
umol/l
—
8
39
239
2294
1.29
0.75
31.5
13.1
30.54
23.07
mg/l
2.54
219
1806
5
28
1.80
0.66
2.0
2.1
13.38
13.32
%
—
5
28
11
70
1.59
0.66
2.1
1.2
9.38
11.32
g/l
0.80
11
63
16
221
0.71
0.63
2.0
2.0
3.84
3.38
ratio
0.79
16
183
39
473
0.80
0.63
1.3
1.3
43.90
38.99
iu/ml
0.07
16
143
142
1527
0.86
0.61
3.3
3.1
—
—
—
0
0
0
20
0.00
0.60
0.0
1.0
—
18.91
—
0
20
92
823
1.18
0.60
4.1
4.1
20.27
28.71
mg/mmol
0.15
57
518
12
81
1.50
0.58
2.3
1.2
3.49
3.85
g/l
0.68
12
74
12
81
1.50
0.58
2.3
1.2
7.78
7.33
g/l
0.39
12
74
12
81
1.50
0.58
2.3
1.2
4.03
4.45
g/l
0.90
12
74
35
422
0.81
0.54
1.3
1.3
3.95
13.58
u/ml
—
10
161
18
134
1.37
0.54
24.2
5.2
0.64
0.58
%
0.27
18
134
9
61
1.49
0.54
1.0
1.2
—
—
—
0
0
223
2148
1.19
0.52
7.2
6.6
39.74
39.55
mmol/mol
0.13
216
2026
11
76
1.47
0.49
2.0
1.6
—
—
—
0
0
7
46
1.53
0.48
1.1
1.4
—
—
—
0
0
230
2227
1.18
0.47
5.5
5.2
4.76
4.59
mmol/l
1.39
217
2088
249
2544
0.81
0.47
48.9
20.1
4.35
4.54
e12/l
6.46
242
2467
19
147
1.31
0.46
2.2
2.1
—
—
—
0
0
249
2543
0.81
0.45
49.1
20.1
269.29
249.64
e9/l
3.39
243
2472
16
122
1.33
0.43
1.9
2.0
—
—
—
0
0
5
34
1.48
0.40
1.6
2.3
105.00
105.76
mmol/l
—
5
34
5
34
1.48
0.40
1.6
2.3
1.19
1.18
mmol/l
—
5
34
219
2121
1.15
0.40
4.8
4.3
1.55
1.27
mmol/l
3.79
203
1958
5
37
1.36
0.37
1.0
1.2
—
—
—
0
0
11
81
1.37
0.37
1.9
1.6
—
—
—
0
0
24
285
0.83
0.34
3.7
5.2
31.06
31.23
%
0.02
17
183
231
2253
1.14
0.34
6.1
6.0
2.73
2.70
mmol/l
0.21
217
2105
22
183
1.22
0.33
2.3
2.3
0.14
0.24
e6/l
0.55
22
174
10
74
1.36
0.32
1.5
1.6
—
0.19
—
0
15
6
47
1.28
0.32
1.2
1.4
—
83.33
—
0
6
10
130
0.76
0.30
1.0
1.3
—
—
—
0
0
227
2218
1.12
0.29
5.4
5.1
1.42
1.46
mmol/l
0.57
212
2063
42
378
1.13
0.26
2.0
1.7
1258.46
1215.95
nmol/l
0.09
30
294
8
67
1.20
0.26
1.6
1.6
—
—
—
0
0
9
77
1.17
0.24
1.6
1.2
3.07
2.88
g/l
—
9
70
5
42
1.19
0.21
1.2
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
0.96
—
0
13
6
48
1.26
0.20
1.3
1.4
—
—
—
0
0
51
548
0.92
0.19
3.9
3.7
1.02
1.02
kg/l
0.42
38
356
59
628
0.92
0.18
1.4
1.5
0.76
1.88
u/ml
1.66
19
167
54
576
0.92
0.18
3.8
3.6
21.10
24.86
%
0.52
28
259
21
186
1.14
0.17
1.5
1.5
—
—
—
0
0
8
71
1.13
0.16
1.1
1.2
—
—
—
0
0
9
81
1.11
0.15
1.2
1.5
—
—
—
0
0
9
83
1.09
0.15
1.9
1.2
1.14
0.91
g/l
—
9
83
44
414
1.07
0.13
2.9
2.7
0.91
0.75
ug/l
0.30
26
252
27
253
1.07
0.09
2.0
2.1
—
—
—
0
0
244
2421
1.06
0.09
22.4
10.0
26.76
26.55
u/l
0.05
237
2333
10
94
1.07
0.01
1.9
1.5
—
—
—
0
0
34
338
1.01
0.00
1.4
1.4
—
—
—
0
0
72
719
1.00
0.00
5.0
3.9
2.86
1.83
ug/l
0.56
59
642
28
285
0.98
0.00
2.0
2.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
105.20
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
10.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
6
59
1.02
0.00
1.2
1.3
—
54.06
—
0
5
0
5
0.00
0.00
0.0
7.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
78
0.89
-0.00
1.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
7
76
0.92
-0.00
1.7
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
79
0.88
-0.00
1.0
1.2
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
7
0.00
-0.00
0.0
1.1
—
110.14
—
0
7
8
82
0.97
-0.00
1.3
1.1
1.58
1.51
g/l
—
8
82
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
40.80
—
0
9
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
7
0.00
-0.00
0.0
2.6
—
137.29
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_ADRENAL_GLAND_WIDE – Malignant neoplasm of adrenal gland, including Hilmo
GWS hits: 1
This endpoint is excluded (different definition than used in FinnGen).